Thyroid disease

Risk of Incident Thyroid Dysfunction in the Post-Acute Phase of COVID-19: A Population-Based Cohort Study in Hong Kong

Endocr PractPublished Retrospective cohort study

Main finding · Diagnosed thyroid dysfunction (composite), post-acute phaseResult — go to the resultHazard ratio 1.058 95% CI 0.979–1.144

Authors' conclusion

Our population-based cohort study provided important reassuring data that COVID-19 was unlikely to be associated with persistent effects on thyroid function.

Study context

Population
COVID-19 patients and non-COVID-19 individuals, January 2020–March 2022, electronic medical records of the Hong Kong Hospital Authoritymatched cohort
Participants
84,034 vs 84,034
Exposure
COVID-19 vs matched non-COVID-19 controls
  • COVID-19n = 84,034
  • Controlsn = 84,034reference
Outcome
Composite of thyroid dysfunction (hyperthyroidism, hypothyroidism, initiation of antithyroid drug or levothyroxine, and thyroiditis) in the post-acute phase
Follow-up
Median 303 days
Methodological detailspropensity-score matched, population-based, 1:1 matched, Cox regression; follow-up until outcome, death, or 31 January 2023
  • Propensity-score matched
  • Population-based
  • 1:1 matched
  • Cox regression; follow-up until outcome, death, or 31 January 2023

Main finding

As reported in the abstract

Diagnosed thyroid dysfunction (composite), post-acute phase

Hazard ratio

1.058

95% CI 0.979–1.144

P = 0.154

COVID-19vs Controls
HR 1.058 (95% CI 0.979–1.144); P = 0.154

Observational data: associations, not effects.

Secondary outcomes

OutcomeHRP value
Hyperthyroidism1.061P = 0.345
Hypothyroidism1.062P = 0.255
Initiation of antithyroid drug1.302P = 0.070
Initiation of LT41.086P = 0.426
ThyroiditisNo increased riskP = 0.252

Subgroup and sensitivity analyses

Largely consistent with the main analyses

Original publication

Risk of Incident Thyroid Dysfunction in the Post-Acute Phase of COVID-19: A Population-Based Cohort Study in Hong Kong. Endocr Pract. Published 28 March 2024. doi:10.1016/j.eprac.2024.03.389

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.